Financial Performance - For the six months ended June 30, 2023, the revenue was approximately RMB 639.5 million, an increase of about 15.2% compared to RMB 555.2 million for the same period in 2022[2]. - The gross profit for the same period was approximately RMB 504.8 million, representing a growth of about 14.3% from RMB 441.6 million in the previous year[2]. - The net profit attributable to the owners of the company was approximately RMB 220.2 million, an increase of about 2.5% from RMB 214.8 million in the same period of 2022[2]. - The operating profit for the six months ended June 30, 2023, was RMB 255.2 million, compared to RMB 237.9 million for the same period in 2022[4]. - The company reported a pre-tax profit of RMB 256,421 thousand for the six months ended June 30, 2023, compared to RMB 240,620 thousand for the same period in 2022, marking an increase of approximately 6.6%[12][13]. - The company reported other income and gains of RMB 54,980 thousand for the first half of 2023, compared to RMB 49,823 thousand for the same period in 2022, indicating a growth of about 4.3%[12][13]. - The company's pre-tax profit for the six months ended June 30, 2023, was RMB 182,781,000, compared to RMB 151,724,000 in 2022, reflecting a growth of 20.5%[17]. - Basic and diluted earnings per share for the six months ended June 30, 2023, were RMB 220,164,000, compared to RMB 214,784,000 in 2022, showing a slight increase of 2.1%[21]. Assets and Liabilities - The total assets less current liabilities amounted to RMB 3,447.1 million as of June 30, 2023, compared to RMB 3,105.4 million at the end of 2022[6]. - Non-current assets increased to RMB 2,147.4 million as of June 30, 2023, from RMB 2,293.4 million at the end of 2022[5]. - The company reported cash and cash equivalents of RMB 775.1 million as of June 30, 2023, down from RMB 833.8 million at the end of 2022[5]. - The net assets of the company increased to RMB 3,256.4 million as of June 30, 2023, compared to RMB 2,921.1 million at the end of 2022[6]. - Total assets as of June 30, 2023, reached RMB 4,081,898 thousand, an increase from RMB 3,690,103 thousand as of December 31, 2022, indicating a growth of approximately 10.6%[14]. - The total liabilities as of June 30, 2023, were RMB 825,471 thousand, compared to RMB 769,046 thousand as of December 31, 2022, reflecting an increase of about 7.3%[15]. - As of June 30, 2023, the total current assets of the group were approximately RMB 1,934.5 million, an increase of about 38.4% from RMB 1,396.7 million as of December 31, 2022[56]. - The total current liabilities as of June 30, 2023, were approximately RMB 634.8 million, up from RMB 584.7 million as of December 31, 2022, representing an increase of about 8.9%[56]. Research and Development - Research and development expenses for the first half of 2023 amounted to RMB 110,607 thousand, slightly increasing from RMB 100,261 thousand in the same period of 2022, reflecting a focus on innovation and product development[12][13]. - The company submitted 82 patent applications and successfully obtained 91 patents during the six months ended June 30, 2023, bringing the total number of effective patent applications to 1,904, with 842 patents approved[39]. - The company continues to enhance its innovation capabilities and accelerate product development to maintain its industry-leading position[38]. - R&D expenses increased by approximately 10.3% to about RMB 110.6 million for the six months ended June 30, 2023, compared to approximately RMB 100.3 million for the same period in 2022[47]. Market and Sales - Revenue from the domestic market accounted for approximately 80.4% of total revenue, while overseas markets contributed approximately 19.6%, with Asia (excluding mainland China) and Europe accounting for about 8.5% and 7.5% respectively[36]. - Revenue from the structural heart disease business was approximately RMB 243.9 million, representing an increase of about 25.1% compared to RMB 194.9 million in the same period of 2022[41]. - Revenue from the peripheral vascular business was approximately RMB 362.7 million, an increase of about 14.6% compared to RMB 316.6 million in the same period of 2022[41]. - The company has established a stable global sales network with distributors in multiple countries across Asia, Africa, North America, South America, and Europe[35]. - The company focuses on advanced minimally invasive medical devices for treating cardiovascular and peripheral vascular diseases[35]. Employee and Administrative Costs - As of June 30, 2023, the company employed 1,391 full-time employees, an increase from 1,299 as of December 31, 2022[68]. - Total employee costs for the six months ended June 30, 2023, amounted to approximately RMB 182.8 million, compared to RMB 151.7 million for the same period in 2022, reflecting a year-on-year increase of 20.5%[68]. - Administrative expenses rose by approximately 29.5% to about RMB 59.7 million, mainly due to increased employee costs and travel expenses[46]. - Sales and distribution expenses increased by approximately 20.9% to about RMB 119.2 million, primarily due to increased marketing and travel expenses[45]. Dividends and Shareholder Returns - The company did not recommend any interim dividend for the six months ended June 30, 2023, consistent with the previous year[2]. - The board did not recommend any interim dividend for the six months ended June 30, 2023, consistent with the same period in 2022[74]. Compliance and Governance - The company has adopted the corporate governance code as per the Stock Exchange Listing Rules and confirmed compliance with all significant provisions as of June 30, 2023[75]. - The Audit Committee, consisting of three independent non-executive directors, has reviewed the interim results for the six months ending June 30, 2023, ensuring compliance with relevant accounting standards and legal requirements[77]. - The company has confirmed that all board members adhered to the securities trading standard code during the six months ending June 30, 2023[76].
先健科技(01302) - 2023 - 中期业绩